Wednesday, November 08, 2017 9:18:58 AM
BPMX - .2089 Pre-market now at .25/.26
BioPharmX Receives Concurrence from FDA on Phase 3 Acne Study Plans
BZ: UPDATE: BioPharmX Announces FDA Offered Positive Feedback Related To Design Of Co.'s Planned Phase 3 Trial For BPX-01
BioPharmX Receives Concurrence from FDA on Phase 3 Acne Study Plans
BZ: UPDATE: BioPharmX Announces FDA Offered Positive Feedback Related To Design Of Co.'s Planned Phase 3 Trial For BPX-01
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
